Perioperative Management of Hydroxyurea and Anagrelide for Knee Replacement
Continue hydroxyurea through the perioperative period and hold anagrelide for at least 1-2 days before surgery, resuming once wound healing is adequate (approximately 2 weeks postoperatively).
Rationale and Evidence-Based Approach
Hydroxyurea Management
The available evidence does not specifically address hydroxyurea perioperative management in the context of joint replacement surgery. The 2022 ACR/AAHKS guidelines 1 focus on antirheumatic medications but do not include hydroxyurea or cytoreductive agents for myeloproliferative disorders. The FDA label 2 emphasizes myelosuppression monitoring but provides no surgical guidance.
In the absence of specific guidelines, the safest approach is to continue hydroxyurea through surgery because:
- Abrupt discontinuation risks rebound thrombocytosis in essential thrombocythemia or polycythemia vera, potentially increasing thrombotic complications
- The drug's primary concern is myelosuppression, which should be assessed preoperatively through complete blood counts
- Unlike immunosuppressive biologics, hydroxyurea does not have the same infection risk profile that necessitates perioperative holding
Anagrelide Management
Anagrelide should be held perioperatively based on the following considerations:
- Anagrelide has platelet-specific action and a short half-life (approximately 1.3 hours)
- Recent meta-analysis 3 demonstrates anagrelide's association with higher bleeding risk compared to hydroxyurea
- The drug can be safely held for 1-2 days preoperatively without significant rebound thrombocytosis due to its short duration of action
- Resume approximately 2 weeks postoperatively once wound healing is established and surgical drains are removed 4
Preoperative Assessment Requirements
Before proceeding with surgery, verify:
- Complete blood count within 1-2 weeks of surgery: Ensure platelet count is controlled (ideally <400,000/μL) and no significant anemia or leukopenia exists
- Hematology consultation: Coordinate with the patient's hematologist regarding optimal platelet targets and timing
- Bleeding history: Document any prior bleeding complications or thrombotic events
Critical Perioperative Considerations
Thrombotic Risk
- JAK2-positive patients have higher thrombotic event rates (23% vs 10% in JAK2-negative) 3
- Consider extended thromboprophylaxis protocols in high-risk patients
- Monitor for signs of deep vein thrombosis or pulmonary embolism
Bleeding Risk
- Anagrelide carries higher bleeding risk than hydroxyurea 3
- Ensure adequate hemostasis intraoperatively
- Consider tranexamic acid use per institutional protocols
Wound Healing
- Monitor closely for wound complications given potential platelet dysfunction
- Do not restart anagrelide until sutures/staples removed and no signs of infection 4
Common Pitfalls to Avoid
- Do not hold hydroxyurea for extended periods - This risks dangerous platelet rebound
- Do not restart anagrelide too early - Wait for complete wound healing to minimize bleeding complications
- Do not ignore preoperative platelet counts - Extreme thrombocytosis (>1,000/μL) may require surgery delay
- Do not forget hematology coordination - These patients require multidisciplinary management
Postoperative Monitoring
- Daily CBC for first 3-5 days postoperatively
- Resume anagrelide at approximately 2 weeks when wound demonstrates healing
- Monitor platelet counts weekly for first month after restarting medications
- Watch for signs of infection given myelosuppressive effects of hydroxyurea 2